吉田修
著書 > 論文

国立情報学研究所収録論文 国立情報学研究所
膀胱（尿路上皮）がんの研究
Miyakawa M, Yoshida O.
DNA synthesis of the urinary bladder epithelium in rats with long-term feeding of dl-tryptophan-added and pyridoxine-deficient diet.
Gann. 1973 Aug;64(4):411-3.
Miyakawa M, Yoshida O.
Protective effects of DL-tryptophan on benzidine-induced hepatic tumor in mice.
Gann. 1980 Apr;71(2):265-8.
Fujita J, Yoshida O, Yuasa Y, Rhim JS, Hatanaka M, Aaronson SA.
Ha-ras oncogenes are activated by somatic alterations in human urinary tract tumours.
Nature. 1984 May 31-Jun 6;309(5967):464-6.
Fujita J, Ohuchi N, Ito N, Reynolds SH, Yoshida O, Nakayama H, Kitamura Y.
Activation of H-ras oncogene in rat bladder tumors induced by N-butyl-N-(4-hydroxybutyl)nitrosamine.
J Natl Cancer Inst. 1988 Mar 2;80(1):37-43.
Habuchi T, Takahashi R, Yamada H, Ogawa O, Kakehi Y, Ogura K, Hamazaki S, Toguchida J, Ishizaki K, Fujita J, Sugiyama T, Yoshida O.
Influence of cigarette smoking and schistosomiasis on p53 gene mutation in urothelial cancer.
Cancer Res. 1993 Aug 15;53(16):3795-9.
Habuchi T, Takahashi R, Yamada H, Kakehi Y, Sugiyama T, Yoshida O.
Metachronous multifocal development of urothelial cancers by intraluminal seeding.
Lancet. 1993 Oct 30;342(8879):1087-8.
Habuchi T, Ogawa O, Kakehi Y, Ogura K, Koshiba M, Hamazaki S, Takahashi R, Sugiyama T, Yoshida O.
Accumulated allelic losses in the development of invasive urothelial cancer.
Int J Cancer. 1993 Feb 20;53(4):579-84.
Habuchi T, Kinoshita H, Yamada H, Kakehi Y, Ogawa O, Wu WJ, Takahashi R, Sugiyama T, Yoshida O.
Oncogene amplification in urothelial cancers with p53 gene mutation or MDM2 amplification.
J Natl Cancer Inst. 1994 Sep 7;86(17):1331-5.
Okuno H, Kakehi Y, Ozdemir E, Terachi T, Okada Y, Yoshida O.
Association of in vitro growth potential of urinary exfoliated cells with tumor localization and intraluminal recurrence rates of urothelial cancers.
J Urol. 1997 Nov;158(5):1996-9.
Habuchi T, Yoshida O, Knowles MA.
A novel candidate tumour suppressor locus at 9q32-33 in bladder cancer: localization of the candidate region within a single 840 kb YAC.
Hum Mol Genet. 1997 Jun;6(6):913-9.
Kinoshita H, Ogawa O, Kakehi Y, Mishina M, Mitsumori K, Itoh N, Yamada H, Terachi T, Yoshida O.
Detection of telomerase activity in exfoliated cells in urine from patients with bladder cancer.
J Natl Cancer Inst. 1997 May 21;89(10):724-30.
腎臓がんの研究
Kakehi Y, Kanamaru H, Yoshida O, Ohkubo H, Nakanishi S, Gottesman MM, Pastan I.
Measurement of multidrug-resistance messenger RNA in urogenital cancers; elevated expression in renal cell carcinoma is associated with intrinsic drug resistance.
J Urol. 1988 Apr;139(4):862-5.
Hashimura T, Tubbs RR, Connelly R, Caulfield MJ, Trindade CS, McMahon JT, Galetti TP, Edinger M, Sandberg AA, Dal Cin P, Sait S.J, Pontes J.E.
Characterization of two cell lines with distinct phenotypes and genotypes established from a patient with renal cell carcinoma.
Cancer Res. 1989 Dec 15;49(24 Pt 1):7064-71.
Kakehi Y, Yoshida O.
Restriction fragment length polymorphism of the L-myc gene and susceptibility to metastasis in renal cancer patients.
Int J Cancer. 1989 Mar 15;43(3):391-4.
Kanamaru H, Kakehi Y, Yoshida O, Nakanishi S, Pastan I, Gottesman MM.
MDR1 RNA levels in human renal cell carcinomas: correlation with grade and prediction of reversal of doxorubicin resistance by quinidine in tumor explants.
J Natl Cancer Inst. 1989 Jun 7;81(11):844-9.
Ogawa O, Kakehi Y, Ogawa K, Koshiba M, Sugiyama T, Yoshida O.
Allelic loss at chromosome 3p characterizes clear cell phenotype of renal cell carcinoma.
Cancer Res. 1991 Feb 1;51(3):949-53.
Ogawa O, Habuchi T, Kakehi Y, Koshiba M, Sugiyama T, Yoshida O.
Allelic losses at chromosome 17p in human renal cell carcinoma are inversely related to allelic losses at chromosome 3p.
Cancer Res. 1992 Apr 1;52(7):1881-5.
Okamoto K, Toyokuni S, Uchida K, Ogawa O, Takenewa J, Kakehi Y, Kinoshita H, Hattori-Nakakuki Y, Hiai H, Yoshida O.
Formation of 8-hydroxy-2'-deoxyguanosine and 4-hydroxy-2-nonenal-modified proteins in human renal-cell carcinoma.
Int J Cancer. 1994 Sep 15;58(6):825-9.
Oka H, Chatani Y, Hoshino R, Ogawa O, Kakehi Y, Terachi T, Okada Y, Kawaichi M, Kohno M, Yoshida O.
Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma.
Cancer Res.
1995 Sep 15;55(18):4182-7.
Okamoto K, Toyokuni S, Kim WJ, Ogawa O, Kakehi Y, Arao S, Hiai H, Yoshida O.
Overexpression of human mutT homologue gene messenger RNA in renal-cell carcinoma: evidence of persistent oxidative stress in cancer.
Int J Cancer. 1996 Feb 8;65(4):437-41.
Kim WJ, Kakehi Y, Kinoshita H, Arao S, Fukumoto M, Yoshida O.
Expression patterns of multidrug-resistance (MDR1), multidrug resistance-associated protein (MRP),glutathione-S-transferase-pi (GST-pi) and DNA topoisomerase II (Topo II) genes in renal cell carcinomas and normal kidney.
J Urol. 1996 Aug;156(2 Pt 1):506-11.
Ozdemir E, Kakehi Y, Nakamura E, Kinoshita H, Terachi T, Okada Y, Yoshida O.
HLA-DRB1*0101 and *0405 as protective alleles in Japanese patients with renal cell carcinoma.
Cancer Res.
1997 Feb 15;57(4):742-6.
前立腺がんの研究
Okabe T, Ackermann R, Wirth M, Frohmüller HG.
Cell-mediated cytotoxicity in patients with cancer of the prostate.
J Urol. 1979 Nov;122(5):628-32.
Oishi K, Okada K, Yoshida O, Yamabe H, Ohno Y, Hayes RB, Schroeder FH.
A case-control study of prostatic cancer with reference to dietary habits.
Prostate. 1988;12(2):179-90.
Okada K, Oishi K, Yoshida O, Sudo K, Kawase M, Nakayama R.
Study of the effect of an anti-androgen (oxendolone) on experimentally induced canine prostatic hyperplasia. I. Morphological analysis.
Urol Res. 1988;16(2):67-72.
Okada K, Oishi K, Yoshida O, Sudo K, Kawase M, Nakayama R.
Study of the effect of an anti-androgen (oxendolone) on experimentally induced canine prostatic hyperplasia. II. Endocrinological analysis.
Urol Res. 1988;16(2):73-8.
Oishi K, Okada K, Yoshida O, Yamabe H, Ohno Y, Hayes RB, Schroeder FH.
Case-control study of prostatic cancer in Kyoto, Japan: demographic and some lifestyle risk factors.
Prostate. 1989;14(2):117-22.
Arai Y, Yoshiki T, Yoshida O.
Prognostic significance of prostate specific antigen in endocrine treatment for prostatic cancer.
J Urol. 1990 Dec;144(6):1415-9.
Oishi K, Okada K, Yoshida O, Yamabe H, Ohno Y, Hayes RB, Schroeder FH, Boyle P.
A case-control study of prostatic cancer in Kyoto, Japan: sexual risk factors.
Prostate. 1990;17(4):269-79.
de Jong FH, Oishi K, Hayes RB, Bogdanowicz JF, Raatgever JW, van der Maas PJ, Yoshida O, Schroeder FH.
Peripheral hormone levels in controls and patients with prostatic cancer or benign prostatic hyperplasia: results from the Dutch-Japanese case-control study.
Cancer Res. 1991 Jul 1;51(13):3445-50.
Arai Y, Takeuchi H, Oishi K, Yoshida O.
Osteocalcin: is it a useful marker of bone metastasis and response to treatment in advanced prostate cancer?
Prostate. 1992;20(3):169-77.
Arai Y, Yoshida O.
A heterogeneous pattern of progression in endocrine-treated patients with prostate cancer.
Eur Urol. 1996;29(3):331-6.
Fujikawa K, Sasaki M, Arai Y, Yamabe H, Ogawa O, Yoshida O.
Prognostic criteria in patients with prostate cancer: Gleason score versus volume-weighted mean nuclear volume.
Clin Cancer Res. 1997 Apr;3(4):613-8.
Arai Y, Yoshiki T, Yoshida O.
c-erbB-2 oncoprotein: a potential biomarker of advanced prostate cancer.
Prostate. 1997 Feb 15;30(3):195-201.
その他の泌尿器疾患に関する研究
Komatz Y, Yoshida O.
Finger patterns and ridge counts of patients with Klinefelter's syndrome (47, XXY) among the Japanese.
Hum Hered. 1976;26(4):290-7.
Takeuchi H, Kobashi K, Yoshida O.
Prevention of infected urinary stones in rats by urease inhibitor: a new hydroxamic acid derivative.
Invest Urol. 1980 Sep;18(2):102-5.
Okada Y, Arai Y, Oishi K, Takeuchi H, Yoshida O.
Stable formation of the nipple valve in Kock pouch for diversion of the urinary tract.
Surg Gynecol Obstet. 1989 Oct;169(4):315-8.
Hida S, Okada K, Yoshida O.
Advantages in combination chemotherapy using cisplatin and its analogues for human testicular tumor xenografts.
Jpn J Cancer Res. 1990 Apr;81(4):425-30.
Matsuda T, Horii Y, Yoshida O.
Should the testicular artery be preserved at varicocelectomy?
J Urol. 1993 May;149(5 Pt 2):1357-60.
Arai Y, Kawakita M, Terachi T, Oishi K, Okada Y, Takeuchi H, Yoshida O.
Long-term followup of the Kock and Indiana pouch procedures.
J Urol. 1993 Jul;150(1):51-5.
Matsuda T, Terachi T, Yoshida O.
Laparoscopic Adrenalectomy: The Surgical Technique and Initial Results of 13 cases.
Min Invas Ther. 1993 2:123-7.
Matsuda T, Horii Y, Yoshida O.
Obstructive azoospermia of unknown origin: sites of obstruction and surgical outcomes.
J Urol. 1994 Jun;151(6):1543-6.
Terai A, Arai Y, Kawakita M, Okada Y, Yoshida O.
Effect of urinary intestinal diversion on urinary risk factors for urolithiasis.
J Urol. 1995 Jan;153(1):37-41.
Arai Y, Kawakita M, Hida S, Terachi T, Okada Y, Yoshida O.
Psychosocial aspects in long-term survivors of testicular cancer.
J Urol. 1996 Feb;155(2):574-8.
Arai Y, Fukuzawa S, Terai A, Yoshida O.
Transurethral microwave thermotherapy for benign prostatic hyperplasia: relation between clinical response and prostate histology.
Prostate. 1996 Feb;28(2):84-8.
Ozdemir E, Kakehi Y, Mishina M, Ogawa O, Okada Y, Ozdemir D, Yoshida O.
High-resolution HLA-DRB1 and DQB1 genotyping in Japanese patients with testicular germ cell carcinoma.
Br J Cancer. 1997;76(10):1348-52.
Arai Y, Kawakita M, Okada Y, Yoshida O.
Sexuality and Fertility in Long-Term Survivors of Testicular Cancer.
J Clin Oncol. 1997;15:1444-8.
Terachi T, Matsuda T, Terai A, Ogawa O, Kakehi Y, Kawakita M, Shichiri Y, Mikami O, Takeuchi H, Okada Y, Yoshida O.
Transperitoneal laparoscopic adrenalectomy: experience in 100 patients.
J Endourol. 1997 Oct;11(5):361-5.
Ueda T, Yoshimura N, Yoshida O.
Diabetic cystopathy: relationship to autonomic neuropathy detected by sympathetic skin response.
J Urol. 1997 Feb;157(2):580-4.
Yamamoto S, Tsukamoto T, Terai A, Kurazono H, Takeda Y, Yoshida O.
Genetic evidence supporting the fecal-perineal-urethral hypothesis in cystitis caused by Escherichia coli.
J Urol. 1997 Mar;157(3):1127-9.
他1291編